Surgical replacement of aortic valve is the gold standard therapy for severe aortic valve stenosis. Transcatheter Aortic Valve Implantation (TAVI) is less invasive and becomes an alternative therapy reserved for patients with high operative risk. TAVI can be performed via transfemoral, transapical or transaortic approach. Patients with diseased or difficult femoral/iliac vascular access, poor left ventricular function and significant respiratory disease are not suitable for transfemoral or transapical approach. In this scenario, direct transaortic approach of TAVI is a feasible option. This case report presents a case of a 76-year-old man with symptomatic severe aortic valve stenosis who underwent general anaesthesia and was successfully treated by direct transaortic TAVI using Edwards Sapien XT aortic bioprosthesis.
INTRODUCTION
The classic triad of chest pain, syncope and heart failure is experienced by patients with severe aortic stenosis (AS). The average survival of these patients is limited to 1-3 years 1 . Surgical aortic valve replacement (AVR) with cardiopulmonary bypass is the treatment of choice but a significant number of patients do not undergo AVR because of increased perioperative morbidity and mortality. The use of cardiopulmonary bypass will introduce a unique set of systemic complications, such as stroke, delirium, myocardial dysfunction, reperfusion injury, renal impairment, pulmonary oedema, coagulopathy, inflammatory response, etc.
Transcatheter aortic valve implantation (TAVI) has emerged as a promising alternative therapy to surgical AVR in patients judged to be inoperable or high risk. Transcatheter aortic valve implantation allows the aortic valve to be replaced without sternotomy and cardiopulmonary bypass. There are substantial challenges presented during TAVI procedure and the anaesthesiologists play an essential role in the multidisciplinary team. Transcatheter aortic valve implantation has been performed by various approaches: transfemoral, transapical (TA) and direct aortic (DA) 2 .
CASE REPORT
A 76-year male presented with symptomatic severe AS. His significant co-morbidities included: hypertension, hyperlipidemia, ischaemic heart disease, history of coronary artery bypass graft and percutaneous coronary intervention, permanent pacemaker in situ, symptomatic right carotid stenosis treated by stenting recently. Transthoracic echocardiography revealed severe calcific AS with aortic valve area 0.70 cm 2 , mean pressure gradient of 37 mmHg, peak pressure gradient 62 mmHg, left ventricular ejection fraction (LVEF) of 54% with hypokinetic apical region. The coronary angiogram showed patent stents and coronary graft segments.
Proceedings of Singapore Healthcare  Volume 24  Number 1  2015 CT abdomen reported diffuse atheromatous changes in thoraco-abdominal aorta, bilateral common iliac and proximal external iliac arteries. Left and right external iliac artery diameters were 6×7 mm and 6×5 mm respectively.
The procedure was carried out under general anaesthesia (GA). The pigtail catheter was inserted via the left common femoral artery, a temporary transvenous pacing wire was advanced through left femoral vein. After upper J-shape mini-sternotomy, patient was heparinised (1.5 mg/kg) so as to achieve target activated clotting time (ACT) more than 250s. The aorta was punctured and aortic valve was crossed with guide-wire-assembly. Balloon aortic valvuloplasty (BAV) was done under rapid ventricular pacing (RVP) at 180 bpm, followed by deployment of aortic valve prosthesis during second RVP ( Fig. 1 ). Aortogram and transoesophageal echocardiography (TEE) demonstrated satisfactory prosthesis position with mild paravalvular aortic regurgitation.
ANAESTHESIA MANAGEMENT
Pre-assessment was performed individually by cardiologists, cardiothoracic surgeons and the cardiac anesthetists. Multidisciplinary team meeting was held pre-operatively between cardiothoracic surgeons, cardiologists, cardiac anaesthetists, operation theatre staff and perfusionists. Dedicated parking areas were assigned to the equipment in the operation theatre. These were: fluoroscopy system, anaesthesia station, TEE machine, defibrillator, Cardio Pulmonary Bypass (CPB) pump, cell-salvage machine, multiple monitors, X-ray lead screens, scrub trolley and prosthesis console. Vasoactive drug infusions such as adrenaline, noradrenaline and glyceryl trinitrate were prepared and placed on standby.
Large bore IV cannula, invasive lines: intra-arterial (IA) line and central venous catheter (CVC) were inserted under standard monitoring and light sedation (IV midazolam 1 mg). Monitoring was applied as following: 5 leads ECG, pulse oximetry, bispectral index and external defibrillator pads. Anaesthesia was induced with midazolam 1 mg, etomidate 8 mg, fentanyl 250 μg and rocuronium 40 mg. The airway was secured with a size 8.0 endotracheal tube. Urinary catheter, nasopharyngeal temperature probe and TEE probe were inserted. Forced air warmer was used. Anaesthesia maintenance was with sevoflurane in oxygen and air, remifentanil infusion (0.05 to 0.1 μg/kg/min), and volume control mechanical ventilation. Phenylephrine bolus and noradrenaline infusion were titrated to maintain mean arterial pressure (MAP) around 70 mmHg.
Coordination between anaesthesiologists and cardiothoracic surgeons was retained at crucial steps. During aortic cannulation and decannulation, systolic blood pressure was maintained around 90-100 mmHg. Prior to RVP, titrated IV bolus of vasopressor Phenylephrine was given to support MAP of 70-80 mmHg as there is a variable period of poor systemic flow.
Intravenous morphine 5 mg and paracetamol 1 g were administered for post-operative analgesia. The patient was extubated on the operating table and transferred to the cardiothoracic surgery intensive care unit (CTSICU) for further monitoring. Proceedings of Singapore Healthcare  Volume 24  Number 1  2015 Subsequently, he was discharged from hospital a week later in a stable condition.
DISCUSSION
The PARTNER trial (Placement of AoRTic TraNscathetER Valve Trial) was a multicentre randomised trial comparing open AVR with TAVI and also TAVI versus medical management and/or balloon aortic valvuloplasty. Transcatheter aortic valve implantation, as compared with standard therapy, significantly reduced the rates of death from any causes, reduced repeat hospitalisation and cardiac symptoms, despite the higher incidence of major strokes and major vascular events 3, 4 . 5 . Clinical assessments should also be performed by a multidisciplinary team 6 .
Transfemoral TAVI is a more common approach, due to its least invasive character. Transapical TAVI completely avoids the passage of arterial system, but represents the most invasive approach 7 . There are risks of apical rupture, pseudoaneurysm formation, deteriorating LV function and respiratory complications from thoracotomy 8 . The DA approach is less invasive than TA, and indicated when the transfemoral approach is contraindicated, e.g. for abnormal/small/atherosclerotic femoral/iliac arteries 9 . In our case, the diseased iliac and femoral vessels and hypokinetic left ventricle apical region indicated a DA approach for TAVI.
Pre-procedure guidelines on antiplatelet agents are not available but it is common practice to administer aspirin 300 mg and clopidogrel 300 mg on the day of the surgery. There is evidence of preserving renal function from contrast agent by good hydration and N-acetylcysteine. Antiarrhythmic and warfarin are discontinued, whereas ACEI are usually continued until surgery.
Preoperatively, it is vital to communicate with the multidisciplinary team and discuss the management of unexpected cardiac arrest during the intraoperative period. In the event, a patient with severe AS sustains cardiac arrest and requires CPR in the process of TAVI, it may be very difficult to restore normal heart rhythm and cardiac function.
Anaesthesiologists who provide support for TAVI must have capabilities in: The ideal location to perform TAVI is a hybrid operation theatre combining features of the cardiovascular catheter laboratory and cardiac theatre 10 . The operation theatre is usually cramped with medical staff and equipment (Fig. 2) . The Patients require extensive monitoring 11 due to severe comorbidities as mentioned in our case. Pulmonary artery catheter and cerebral oximetry are reserved for high risk cases.
General anaesthesia with an endotracheal tube is required for this procedure because:
1. The DA approach requires J-shape partial sternotomy;
2. Patient needs to remain completely still for this procedure;
3. It allows expedient management of sudden haemodynamic deterioration, arrhythmias and initiation of emergency cardiopulmonary bypass if required;
4. Provide optimal conditions for potentially prolonged duration of procedure and surgical repairs of the access sites at the end of the procedure 6 ;
5. It facilitates continuous usage of intraoperative TEE 6 . Intraoperative TEE provides useful information in conjunction with fluoroscopy and aortogram 12 . TEE is very helpful in areas of 13,14 : a. Evaluating aortic annulus for prosthesis, aorta for atheromatous disease, LV function, and any other pathology.
b. Assists with placement of the guidewire, balloon for the balloon angioplasty and prosthesis.
c. Detect any paravalvular or intravalvular aortic regurgitation post-TAVI and any other complications.
Haemodynamic stability is the main objective of anaesthetic management. Goals are those typical of aortic stenosis: adequate preload, low to normal heart rates (50-70 beats/min), normal sinus rhythm and avoid any drop in SVR 10 .
The TAVI procedure could be categorised under four phases: pre-deployment, balloon aortic valvuloplasty, prosthetic aortic valve deployment and post-deployment.
During the pre-deployment phase, cardiologists establish arterial access, introduce and check the The aim of valvuloplasty is to adequately dilate the annulus so as to allow easy insertion of prosthesis. The coordination between the anaesthesiologists and the surgeons is of utmost importance during this period. Balloon aortic valvuloplasty is facilitated by using of RVP at a rate of 180-200 bpm to provide cardiac standstill and is limited to 12-15 seconds. It is advocated to maintain MAP at more than 75 mmHg before the start of RVP and a bolus dose of vasopressor prior to, or immediately after RVP to facilitate rapid return of coronary perfusion 15 .
The deployment of prosthesis also places demands on RVP. The delivery catheter and assembly can obstruct the outflow tract, raising the possibility of a period of haemodynamic instability. The solution is a rapid deployment of the prosthesis. Figure 3 shows the TAVI valve and the fluoroscopic image after deployment. During post deployment, the device position and function is verified and the delivery system is removed to establish forward flow. Patients undergoing TAVI are usually extubated in the operation theatre and transferred to the cardiothoracic ICU for further monitoring 16 .
COMPLICATIONS
To enumerate the risks during the TAVI: 
CONCLUSION
The TAVI procedure poses significant challenges in its anaesthesia management, because of the procedure itself and the patient population. The DA approach is unusual but can be a feasible option in selected patients, such as those with diseased or difficult femoral/iliac vascular access, poor left ventricular function and significant respiratory diseases. A multidisciplinary team approach is essential and work in a hybrid operation theatre is full of challenges for anaesthesiologists. It is important to highlight the importance of good planning, preparation, communication, CPB availability, possibility of surgical AVR, intensive care and support from ancillary personnel for the successful outcome of these procedures.
